LabCentral Houses Scientific Visionaries
Engaged in Early-Stage Research

Amathus Therapeutics

Amathus Therapeutics is developing first-in-class, small-molecule therapeutics designed to enhance mitochondrial function, which have the potential to treat neurodegenerative diseases, such as Parkinson’s disease, and lysosomal-storage disorders — rare, but devastating inherited metabolic diseases that are characterized by an abnormal build-up of various toxic materials in the body's cells as a result of enzyme deficiencies.

Amathus Therapeutics logo
Website - Coming Soon
  • Yiannis Ioannou, PhD Founder & Chair, Scientific Advisory Board
  • Ed Holson, PhD Chief Scientific Officer
  • Ross A. Fredenburg, PhD Director of In Vitro Pharmacology